Endoscopic ultrasound ablation with immunotherapy for pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a procedure that uses sound waves to heat and destroy part of the tumor, combined with an immunotherapy drug called pembrolizumab (Keytruda) that helps your immune system fight the cancer. It is for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has been confirmed by biopsy and cannot be removed by surgery or has spread to other organs.
- You have not had chemotherapy or radiation for this cancer, except if you finished it at least 3 months ago or you have been on first-line treatment for up to 3 months with stable disease.
- You are generally able to care for yourself (ECOG performance status 0-2).
- Your blood counts and liver and kidney function are within acceptable levels.
- You do not have a history of autoimmune disease (like lupus or rheumatoid arthritis) that required systemic steroids, except for conditions like vitiligo or controlled asthma.
- You are not pregnant or breastfeeding and are willing to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach that combines a special type of radiation therapy (called PRaG) with an immunotherapy drug to treat advanced pancreatic cancer that hasn't spread. The goal is to see if this combination can shrink or control the tumor and help you live longer.
This Phase 2 trial is for people with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) confirmed by biopsy. It tests a new treatment strategy after the cancer is diagnosed and considers people who haven’t had certain chemotherapy yet.
This study tests how safe and effective endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is for treating pancreatic growths that might become cancer or already are cancer. It is for people who are already scheduled to have this procedure as part of their care.
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
This trial combines two treatments for advanced pancreatic cancer that hasn't spread: a special endoscopic procedure that uses heat to destroy cancer cells (radiofrequency ablation) and a standard chemotherapy drug combination (FOLFIRINOX). The goal is to see if this combination is safe and can help control the tumor better than chemotherapy alone.
This trial tests a treatment that uses heat from a probe inserted through an endoscope to destroy pancreatic tumors that cannot be removed with surgery. It may help shrink or control the tumor and could be an option if other treatments have not worked.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.